The attack by the one of the most impactful RaaS groups active today demonstrates an evasion strategy that can stump defenses not equipped to detect cross-platform threats.
FDA approves Syndax’s menin inhibitor with black-box warning; GSK’s ADC deal
Plus, news about Regeneron, Innovent, Xencor, MapLight Therapeutics, Genmab, Pfizer, Merck and Ferring Pharmaceuticals: ⬛ Syndax’s Revuforj is approved in another indication: The menin inhibitor can now be used to treat …
Zenas’ multiple sclerosis drug slows new brain lesions in mid-stage trial
Zenas BioPharma’s multiple sclerosis therapy succeeded in a mid-stage trial. The biotech’s shares ZBIO were up about 18% on Monday morning. The company said Monday that 116 patients with relapsing disease …
Novartis CEO says $12B Avidity deal could have been ‘twice as big’
Timing is everything in dealmaking. Novartis’ plan to acquire RNA medicines company Avidity Biosciences for $12 billion was already the second-biggest biotech buyout of the year when it was announced Sunday afternoon …
Takeaways from Endpoints AI Day: Real progress, ‘stupid’ money and moonshots
More than 4,400 of you registered for the second annual Endpoints News AI Day, where I got to interview heavy hitters across the worlds of academia, pharma, biotech and AI labs. So what did we …
CRISPR biotech Intellia plummets as trial paused for safety
Intellia lost 45% of its value today as phase 3 trials of one of its priority drug programmes were halted due to a patient being hospitalised.
WuXi AppTec to divest clinical services to focus on manufacturing business
As WuXi AppTec’s manufacturing revenue recovers, it said it is selling its clinical research services business to a Hong Kong private equity firm. AppTec announced on Monday that its contract research …
Organon CEO resigns over ‘improper’ contraceptive sales
Organon CEO Kevin Ali has stepped down after an audit found sales of the company’s Nexplanon contraceptive implant in the US were inflated.
As Blenrep returns, GSK adds another ADC to cancer pipeline
GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia.
MicroRNA startup Causeway targets raise after results of tendinopathy study
Since launching eight years ago, Causeway Therapeutics has quietly developed a synthetic microRNA molecule it hopes will heal tendon injuries and tested the novel drug in a pair of clinical trials on a slender budget …